Know Cancer

forgot password

A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators

Phase 3
2 Years
Not Enrolling
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis

Thank you

Trial Information

A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators

Inclusion Criteria:

- Male or female patients greater than or equal to 2 years of age

- Documented congenital disorder of red blood cells (e.g., β-thalassemia major, sickle
cell anemia, diamond-blackfan anemia) requiring ongoing blood transfusions

- Cannot be adequately treated with a locally approved iron chelator due to one of the
following reasons:

- Documented non-compliance, defined as having taken less than 50% of the
prescribed chelation therapy doses in the 12 months prior to study entry

- Contraindications, unacceptable toxicities and/or documented poor response to
locally approved iron chelators despite proper compliance

- History of at least 20 blood transfusions (equivalent to 100 mL/kg of packed red
blood cells (PRBC])

- Serum ferritin value greater than or equal to 1000 µg/L

- Ability to comply with all study-related procedures, medications, and evaluations

Exclusion Criteria:

- Ongoing treatment with another iron chelator (Any other iron chelation therapy must
be discontinued at least 24 hours prior to study entry.)

- Patients who meet the eligibility criteria for any other ongoing Novartis sponsored
clinical study protocol with deferasirox and who have geographic access to these

- Patients unable to tolerate (or who have unacceptable toxicities to) prior treatment
with deferasirox

- Serum creatinine above the upper limit of normal at screening.

- Patients with ALT ≥ 500 U/L at screening.

- Evidence of chelation-related cataracts or hearing loss within 4 weeks prior to

- Pregnancy (as indicated by serum β-HCG pregnancy test at screening for all female
patients with the potential to become pregnant) and patients who are breastfeeding

- Patients treated with systemic investigational drug within 4 weeks prior to or with
topical investigational drug within 7 days prior to the baseline visit

Other protocol-defined inclusion/exclusion criteria may apply.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events

Outcome Description:

Safety as assessed by the number of participants with death, serious adverse events (SAE), and/or Adverse Events (AEs) leading to study drug interruption or discontinuation. Note: only treatment emergent AEs are summarized.

Outcome Time Frame:

Baseline to end of study (Median exposure time to drug was approximately 30 weeks; Maximum exposure was 104 weeks)

Safety Issue:


Principal Investigator

Novartis Pharmaceuticals

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals


United States: Food and Drug Administration

Study ID:




Start Date:

October 2005

Completion Date:

October 2008

Related Keywords:

  • Thalassemia
  • Sickle Cell Disease
  • Diamond Blackfan Anemia
  • Myelofibrosis
  • Deferasirox
  • Congenital Anemias
  • Anemias
  • Red Blood Cell Disorders
  • Chronic Iron Overload
  • Transfusional Iron Overload
  • Iron Chelators
  • Oral Iron Chelators
  • Thalassemia
  • Sickle Cell Disease
  • Diamond Blackfan Anemia
  • Myelofibrosis
  • ICL670A
  • Primary Myelofibrosis
  • Anemia
  • Anemia, Sickle Cell
  • Thalassemia
  • Iron Overload
  • Anemia, Diamond-Blackfan



University of Mississippi Medical Center Jackson, Mississippi  39216-4505
Stanford University Stanford, California  94305
Children's Hospital of Orange County Orange, California  92668
Children's Mercy Hospital Kansas City, Missouri  64108
Schneider Children's Hospital New Hyde Park, New York  11042
Children's Hospitals and Clinics of Minnesota Saint Paul, Minnesota  55102
Alta Bates Comprehensive Cancer Center Berkeley, California  94704
Oregon Health & Science University Portland, Oregon  97201
Texas Children's Hospital Houston, Texas  
The Cancer Institute of New Jersey New Brunswick, New Jersey  08901
Hershey Medical Center Hershey, Pennsylvania  17033
James A. Haley Veterans Hospital Tampa, Florida  33612
Arkansas Children's Hospital, UAMS College of Medicine Little Rock, Arkansas  72202
Children's Hospital and Health Center of San Diego San Diego, California  92123
Alfred I. Dupong Hospital for Children Wilmington, Delaware  19803
Osler Medical, Inc. Melbourne, Florida  32901
Hematalogy Oncology Associates Pensacola, Florida  32501
Tampa Children's Hospital at St. Joseph's Hospital Tampa, Florida  33607
Backus Children's Hospital, Memorial Health University Medical Center Savannah, Georgia  31403
Hematalogy Oncology Clinic Baton Rouge, Louisiana  70808
Borgess Hospital Kalamazoo, Michigan  49048
PCTI Columbus, Ohio  43205
The Children's Medical Center of Dayton Dayton, Ohio  45404
Children's Hospitals of Pittsburgh Pittsburgh, Pennsylvania  15213
Children's Hospital of the Kings Daughters Norfolk, Virginia  23507
VCU Pediatric Hematology/Oncology Richmond, Virginia  23219
University of Washington Seattle Cancer Care Alliance Seattle, Washington  98195